Tigecycline: an update

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Tigecycline is a broad-spectrum antibiotic effective against challenging pathogens like MRSA and VRE.
• It exhibits minimal organ toxicity and generally does not require dosage adjustments.
• Clinical studies demonstrate its efficacy and safety comparable to standard therapies for specific infections.

Purpose of the Study:

• To provide an updated overview of tigecycline's clinical utility.
• To review current microbial resistance patterns relevant to tigecycline.
• To analyze pharmacokinetic/pharmacodynamic data and safety profiles.

Main Methods:

• Review of clinical studies on tigecycline.
• Analysis of current antimicrobial resistance data.
• Examination of pharmacokinetic/pharmacodynamic investigations.
• Assessment of safety data and analyses.

Main Results:

• Tigecycline is effective for complicated intra-abdominal infections, skin and skin structure infections, and community-acquired bacterial pneumonia.
• Its use against multidrug-resistant pathogens in hospital-acquired infections requires ongoing evaluation.
• Updated data on resistance patterns and PK/PD are presented.

Conclusions:

• Tigecycline is a valuable option for on-label indications.
• Further assessment is needed for its role in treating infections with high likelihood of multidrug-resistant pathogens.
• The drug presents a favorable safety profile with minimal organ toxicity.